On June 22, Sino Biopharmaceutical fell 3.06% in regular trading, trading at 4.39 HKD/share, with turnover of 50.01 million HKD.

On the news front, the pharmaceutical sector continued to face systematic selling pressure, with peers CSPC Pharmaceutical down 4.35%, Hengrui Pharma down 2.84%, United Laboratories down 3.02%, and Fosun Pharma down 2.99%, reflecting broad industry weakness. Morgan Stanley previously cut the company's target price from 8.3 HKD to 7.8 HKD while maintaining an overweight rating. The stock's short-selling ratio remains elevated at 24.21%, indicating strong bearish positioning and significant market divergence. Additionally, leading pharmaceutical companies have recently initiated large-scale share buybacks to support their stock prices, reflecting insufficient confidence in sector valuations overall.

Sino Biopharmaceutical Limited is an investment holding company principally engaged in pharmaceutical business, operating through segments including modern Chinese medicine preparations and western pharmaceuticals, long-term investments, and related medical and hospital services.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)